Longeveron Inc (LGVN) Stock Price, Quote & News

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 470 2550

Website: longeveron.com

Address:

Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States

7SamuraiScalper Oct. 24 at 10:04 PM

$LGVN Wow...play again? Always liked the mission...

0 · Reply

HoldingontoPennies Oct. 24 at 7:41 PM

$LGVN break it out!

0 · Reply

HoldingontoPennies Oct. 24 at 5:21 PM

$LGVN 👀

0 · Reply

poilu Oct. 24 at 11:31 AM

$LGVN Wish we could go back to June/July prices again.

0 · Reply

babakbb Oct. 24 at 11:29 AM

$LGVN Long on Longeveron. Breakout looks immanent.

0 · Reply

HoldingontoPennies Oct. 22 at 4:26 PM

$LGVN 🥱🥱

0 · Reply

Mangust05 Oct. 21 at 4:14 PM

$LGVN something has to be happening here I can feel it let’s go to $10!

1 · Reply

StockHounding Oct. 19 at 10:24 PM

$BCG price action just keeps tightening—exactly what you want before a range expansion breakout. Still respecting $2.35 swing base and absorbing every pullback. And if you think this is a dilution trap, go read the filings. The POS AM filing on 09/03/25 clarified no ongoing ATM activity and reaffirmed equity structure control . That’s why the float stays locked—no dilution wind pushing against the chart. $CRBP heavy watch for sector rotation $TIVC small float + volume pockets $BNOX rounding base $LGVN momentum stalking I don’t chase noise—I chase structure + filings + liquidity setup. $BCG is a sleeper swing that won’t stay quiet much longer. Accumulate while they distract the herd. 🛑🔥

0 · Reply

Ducmanallja Oct. 17 at 2:56 PM

$LGVN WTF now?

0 · Reply

babakbb Oct. 16 at 8:21 PM

$LGVN Looking very buyable

0 · Reply

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 22, 2025, 9:15 AM EDT - 4 weeks ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 3, 2025, 4:05 PM EDT - 7 weeks ago

Longeveron® Announces Key Leadership Updates

Aug 20, 2025, 9:15 AM EDT - 2 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 10:55 PM EDT - 2 months ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:15 PM EDT - 2 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 2 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Aug 5, 2025, 9:15 AM EDT - 2 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Jul 21, 2025, 9:15 AM EDT - 3 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 8, 2025, 9:15 AM EDT - 3 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jun 26, 2025, 9:05 AM EDT - 4 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 24, 2025, 6:30 AM EDT - 4 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 9, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 20, 2025, 9:15 AM EDT - 5 months ago

Longeveron® to Attend BIO International Convention 2025

May 12, 2025, 7:15 AM EDT - 5 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 9, 2025, 5:31 PM EDT - 6 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025, 8:30 AM EDT - 6 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 11, 2025, 8:30 AM EDT - 8 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 5, 2025, 9:25 AM EST - 8 months ago

Longeveron® to Present at the 37th Annual Roth Conference

Feb 28, 2025, 7:04 PM EST - 8 months ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 4:04 PM EST - 8 months ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 18, 2025, 9:25 AM EST - 8 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Dec 18, 2024, 9:10 AM EST - 11 months ago

Longeveron to Present at Biotech Showcase 2025

Dec 2, 2024, 9:05 AM EST - 11 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Nov 12, 2024, 10:37 PM EST - 1 year ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 7:58 PM EDT - 1 year ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 9, 2024, 9:00 AM EDT - 1 year ago

Neha Motwani Elected to Longeveron® Board of Directors

Jul 8, 2024, 9:00 AM EDT - 1 year ago

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Jun 18, 2024, 4:48 PM EDT - 1 year ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Jun 17, 2024, 9:00 AM EDT - 1 year ago

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Jun 17, 2024, 8:38 AM EDT - 1 year ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Jun 13, 2024, 9:45 AM EDT - 1 year ago

Why has Longeveron stock tripled in two days?

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

7SamuraiScalper Oct. 24 at 10:04 PM

$LGVN Wow...play again? Always liked the mission...

0 · Reply

HoldingontoPennies Oct. 24 at 7:41 PM

$LGVN break it out!

0 · Reply

HoldingontoPennies Oct. 24 at 5:21 PM

$LGVN 👀

0 · Reply

poilu Oct. 24 at 11:31 AM

$LGVN Wish we could go back to June/July prices again.

0 · Reply

babakbb Oct. 24 at 11:29 AM

$LGVN Long on Longeveron. Breakout looks immanent.

0 · Reply

HoldingontoPennies Oct. 22 at 4:26 PM

$LGVN 🥱🥱

0 · Reply

Mangust05 Oct. 21 at 4:14 PM

$LGVN something has to be happening here I can feel it let’s go to $10!

1 · Reply

StockHounding Oct. 19 at 10:24 PM

0 · Reply

Ducmanallja Oct. 17 at 2:56 PM

$LGVN WTF now?

0 · Reply

babakbb Oct. 16 at 8:21 PM

$LGVN Looking very buyable

0 · Reply

HoldingontoPennies Oct. 16 at 6:58 PM

$LGVN 🥱🥱

0 · Reply

babakbb Oct. 16 at 3:33 PM

$LGVN Starter position

0 · Reply

Cbyrd96 Oct. 16 at 2:01 PM

$LGVN should’ve bought more :/

0 · Reply

HoldingontoPennies Oct. 14 at 7:19 PM

$LGVN 🚀😘

0 · Reply

poilu Oct. 10 at 5:23 PM

$LGVN Takes a week to scratch and crawl ALMOST up to $1....THEN drops 8 pennies in a day.

0 · Reply

WSBC Oct. 10 at 4:18 PM

$LGVN nice work management! No funding and no progress and you split the stock when you should’ve known better! But by all means, keep paying yourselves after devastating shareholders…

2 · Reply

Huskersnsaints Oct. 10 at 3:38 PM

$LGVN this thing is just dead!!!!!

0 · Reply

SPYmyQQQ Oct. 9 at 1:52 PM

🎯 Target Hit 🏁 📨 From Sep 17, 2025 💊 $LGVN 💵 Entry: $0.7555 ✅ Exit: $0.9062 💰 P/L: +19.95% 👉 FREE TRIAL! spymyqqq/join/

2 · Reply

BioBuddha Oct. 9 at 11:59 AM

$LGVN I have begun to think this is a scam

1 · Reply

chuppa Oct. 9 at 7:33 AM

$LGVN can this run today?

0 · Reply

Mangust05 Oct. 9 at 3:45 AM

$LGVN I have been here since last year July I got into $RGS and $LGVN. $RGC went from $3.70 to $900 . lgvn has huge room to fly to the moon If They announce good data and partner ship ! Let’s break the wall $1-3-6-10-25-$300!!lfg

0 · Reply

resistancebreakers Oct. 8 at 11:10 PM

$LGVN 🍋🪖🫡☝️

0 · Reply

Market Cap	17.90M
Revenue (ttm)	2.39M
Net Income (ttm)	-15.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-668.20%
Debt to Equity Ratio	0.00

Volume	959,300
Avg Vol	484,998
Day's Range	N/A - N/A
Shares Out	21.06M
Stochastic %K	90%
Beta	0.16
Analysts	Strong Sell
Price Target	$6.86